Faculty Profiles - IWAMURO Masaya

MISC - IWAMURO Masaya

Division display 41 - 60 of about 102 ／ All the affair displays >>

ENDOSCOPIC FEATURES OF LANTHANUM DEPOSITION IN THE GASTRODUODENAL MUCOSA

岩室雅也, 岩室雅也, 神崎洋光, 川野誠司, 河原祥朗, 田中健大, 岡田裕之

Gastroenterological Endoscopy (Web) 59 ( 6 ) 2017

当院での潰瘍性大腸炎患者における上部消化管病変の検討

加藤諒, 岩室雅也, 平岡佐規子, 高嶋志保, 半井明日香, 井口俊博, 岡田裕之

Gastroenterological Endoscopy (Web) 59 ( Supplement2 ) 2017

CD10 down expression in follicular lymphoma correlates with gastrointestinal lesion involving the stomach and large intestine

Nobuhiko Ohnishi, Katsuyoshi Takata, Tomoko Miyata-Takata, Yasuharu Sato, Akira Tari, Yuka Gion, Mai Noujima-Harada, Kohei Taniguchi, Tetsuya Tabata, Keina Nagakita, Shizuma Omote, Hiroyuki Takahata, Masaya Iwamuro, Hiroyuki Okada, Yoshinobu Maeda, Hiroyuki Yanai, Tadashi Yoshino

Cancer Science 107 ( 11 ) 1687 - 1695 2016.11

Follicular lymphoma (FL) shows co-expression of B-cell lymphoma 2 (BCL2) and CD10, whereas downexpression of CD10 is occasionally experienced in gastrointestinal (GI) FL with unknown significance. Gastrointestinal FL is a rare variant of FL, and its similarity with mucosa-associated lymphoid tissue lymphoma was reported. We investigated the clinicopathological and genetic features of CD10 downexpressed (CD10down) GI-FL. The diagnosis of CD10down FL was carried out with a combination of pathological and molecular analyses. The incidence of CD10down GI-FL was shown in 35/172 (20.3%) cases, which was more frequent than nodal FL (3.5%, P < 0.001). The difference was additionally significant between GI-FL and nodal FL when the analysis was confined to primary GI-FL (55.2% vs 3.5%, P < 0.001). Compared to CD10+ GI-FL, CD10down GI-FL significantly involved the stomach or large intestine (P = 0.015), and additionally showed the downexpression of BCL6 (P < 0.001). The follicular dendritic cell meshwork often showed a duodenal pattern in the CD10down group (P = 0.12). Furthermore, a lymphoepithelial lesion was observed in 5/12 (40%) gastric FL cases, which indicated caution in the differentiation of mucosa-associated lymphoid tissue lymphoma. Molecular analyses were undertaken in seven cases of CD10down GI-FL, and an identical clone was found between CD10down follicles and CD10+BCL2+ neoplastic follicles. In the diagnosis of cases with CD10down BCL2+ follicles, careful examination with molecular studies should be carried out.

DOI： 10.1111/cas.13031

Scopus

PubMed

researchmap

臨床例リンパ濾胞性直腸炎に類似した内視鏡像で発症した潰瘍性大腸炎の1例

岩室雅也, 宮部欽生, 高田尚良, 平岡佐規子, 宇田征史

診断と治療 104 ( 10 ) 1346 - 1349 2016.10

Clinicopathological features of 49 primary gastrointestinal diffuse large B-cell lymphoma cases; comparison with location, cell-of-origin, and frequency of MYD88 L265P

Keina Nagakita, Katsuyoshi Takata, Kohei Taniguchi, Tomoko Miyata-Takata, Yasuharu Sato, Akira Tari, Nobuhiko Ohnishi, Mai Noujima-Harada, Shizuma Omote, Naoya Nakamura, Masaya Iwamuro, Yoshinobu Maeda, Hiroyuki Okada, Mitsune Tanimoto, Tadashi Yoshino

Pathology International 66 ( 8 ) 444 - 452 2016.8

The gastrointestinal (GI) tract is the most common primary site of extranodal diffuse large B-cell lymphoma (DLBCL), with approximately one-third of extranodal DLBCL occurring in the GI tract. We investigated the clinicopathological features and immunohistochemically-assessed cell-of-origin of 49 GI DLBCL cases (stomach, 24; small intestine, 10; colon, 15) and also examined the presence of MYD88 L265P as recently this mutation has been frequently identified in ABC-like DLBCL, particularly in extranodal sites. Small intestinal DLBCL was characterized by the preponderance of women (P = 0.041) and elevated LDH (P = 0.002) and soluble interleukin-2 receptor (P = 0.033). Small intestinal DLBCL more frequently showed anemia (P = 0.031) and elevated CRP (P = 0.029) than gastric DLBCL. ABC-like phenotype was seen in 71.4 % cases (stomach, 79 %; small intestine, 70 %; colon, 60 %). MYD88 L265P was detected in 6.1 % cases; all were primary gastric DLBCL with ABC-like phenotype but had no distinct clinicopathological features. In conclusion, GI DLBCL had different clinicopathological features according to the primary site especially in the small intestine. Also, MYD88 L265P had little involvement in GI DLBCL compared with other extranodal DLBCLs, suggesting that its pathogenesis might be different from that of organs with a high frequency of MYD88 L265P.

DOI： 10.1111/pin.12439

Scopus

PubMed

researchmap

症例報告原発不明癌に続発した二次性後腹膜線維症の1例

大重和樹, 岩室雅也, 花山宜久, 長谷川功, 横田智紗子, 萩谷英大, 安藤明美, 松本裕子, 黒田新士, 大塚文男

日本病院総合診療医学会雑誌 10 ( 2 ) 35 - 40 2016.6

Current Status of Treatment Strategy for Sporadic Non-Ampullary Duodenal Adenoma: Japanese Multicenter Retrospective Observation Trial

Hiromitsu Kanzaki, Hiroyuki Sakae, Tatsuhiro Gotoda, Yoshiyasu Kono, Kou Miura, Masaya Iwamuro, Masahide Kita, Seiji Kawano, Yoshiro Kawahara, Hiroyuki Okada

GASTROINTESTINAL ENDOSCOPY 83 ( 5 ) AB324 - AB324 2016.5

Efficacy for the Recognition of Early Gastric Cancer Using Linked Color Imaging (LCI), the Novel Image Enhanced Endoscopy in Terms of the Value of Color Difference

Hiromitsu Kanzaki, Yoshiro Kawahara, Hiroyuki Sakae, Tatsuhiro Gotoda, Yoshiyasu Kono, Kou Miura, Masaya Iwamuro, Masahide Kita, Seiji Kawano, Hiroyuki Okada

GASTROENTEROLOGY 150 ( 4 ) S889 - S890 2016.4

Detection of Minute Duodenal Follicular Lymphoma Lesions Using Magnifying Endoscopy

Iwamuro Masaya, Kondo Eisei, Otsuka Fumio, Takata Katsuyoshi, Yoshino Tadashi, Kawahara Yoshiro, Okada Hiroyuki

Acta Medica Okayama 70 ( 2 ) 139 - 144 2016.4

Letter: promising results of Helicobacter pylori eradication with vonoprazan-based triple therapy after failure of proton pump inhibitor-based triple therapy

T. Inaba, M. Iwamuro, T. Toyokawa, H. Okada

ALIMENTARY PHARMACOLOGY & THERAPEUTICS 43 ( 1 ) 179 - 180 2016.1

Photo Report Eagle症候群の1例

岩室雅也, 大塚文男, 小牧稔幸

内科 117 ( 1 ) 154 - 154 2016.1

Multiple Organomegaly Exhibited in a Patient with Graves' Hyperthyroidism

Kazuki Ocho, Masaya Iwamuro, Fumio Otsuka

INTERNAL MEDICINE 55 ( 18 ) 2737 - 2738 2016

Time-dependent image changes after ethanol injection into the pancreas: an experimental study using a porcine model. International journal

Kazuyuki Matsumoto, Hironari Kato, Koichiro Tsutsumi, Soichiro Fushimi, Masaya Iwamuro, Shinsuke Oda, Sho Mizukawa, Yutaka Akimoto, Daisuke Uchida, Takeshi Tomoda, Naoki Yamamoto, Shigeru Horiguchi, Hiroyuki Okada

Ecancermedicalscience 10 663 - 663 2016

Language：English

BACKGROUND: Ethanol, a commonly available agent, has been used to successfully ablate cystic and solid lesions in the pancreas. The aim of this study is to investigate the effects of an ethanol injection into the porcine pancreas and observe the time-dependent image changes in the pancreatic parenchyma. METHODS: Pure ethanol was injected into the pancreatic tail using a 25-gauge EUS needle with direct ultrasound guidance under celiotomy: 1 mL and 2 mL were injected, respectively. The abdomen was closed after the injection. MRI was performed before the procedure, immediately after, and on postoperative day (POD) seven. Blood samples were taken before the procedure and on PODs one, three, five, and seven. The pigs were euthanised on POD seven. RESULTS: Immediately after the injection, linear high signal areas in the pancreatic tail on T2 and rounded speckled high signal areas on DWI images were detected in both animals, measuring 35 × 32 mm in the 1 mL injected pig and 42 × 38mm in the 2 mL injected pig. After POD seven, rounded high signal areas were noted on T2 images, measuring 22 × 18 mm and 36 × 28 mm respectively. On POD one, the 1 mL injected animal had a 53% elevation in serum amylase while the 2 mL injected animal had a 66% elevation. Histologically, cystic and necrotic changes in the parenchyma were observed, measuring 23 × 22 mm and 40 × 35 mm respectively. CONCLUSIONS: Our results, which are limited to normal pancreas, suggested that a 1 mL injection caused localised changes within the pancreas while a 2 mL injection induced more widespread changes beyond the pancreas. The effective area of ethanol was widespread immediately after injection, and then the area was reduced with cystic and necrosis changes.

DOI： 10.3332/ecancer.2016.663

PubMed

researchmap

Novel REIC/Dkk-3-encoding adenoviral vector as a promising therapeutic agent for pancreatic cancer

H. Sawahara, H. Shiraha, D. Uchida, H. Kato, T. Nagahara, M. Iwamuro, J. Kataoka, S. Horiguchi, M. Watanabe, M. Sakaguchi, A. Takaki, K. Nouso, Y. Nasu, H. Kumon, H. Okada

Cancer Gene Therapy 23 ( 8 ) 278 - 283 2016

Primary Duodenal Follicular Lymphoma Treated With Rituximab Monotherapy and Followed-up for 15 Years

Seki Anna, Iwamuro Masaya, Yoshioka Masao, Fujii Nobuharu, Okada Hiroyuki, Nose Soichiro, Takata Katsuyoshi, Yoshino Tadashi, Yamamoto Kazuhide

Acta Medica Okayama 69 ( 5 ) 301 - 306 2015.10

原発性小腸癌34例の治療成績

秋元悠, 那須淳一郎, 岩室雅也, 神崎洋光, 堤康一郎, 喜多雅英, 川野誠司, 原田馨太, 加藤博也, 平岡佐規子, 河原祥朗, 八木孝仁, 大塚文男, 岡田裕之

日本病院総合診療医学会雑誌 9 ( 1 ) 23 - 29 2015.10

Language：Japanese Publisher：(一社)日本病院総合診療医学会

当院の原発性小腸癌患者34例の治療成績を解析した。原発部位は十二指腸29例、空腸3例、回腸1例、空腸または回腸1例、臨床病期はStage I 11例、Stage II 5例、Stage III 6例、Stage IV 12例。治療内容は、Stage Iでは内視鏡的切除5例と手術6例、Stage II/Stage IIIでは全例手術、Stage IVでは化学療法のみが3例、化学療法+原発巣切除が3例、原発巣切除+転移巣切除が4例、緩和治療が2例で、5年生存率はStage I/IIが80%、Stage IIIが33%、Stage IVが39%であった。(著者抄録)

CiNii Article

researchmap

Other Link： http://search.jamas.or.jp/link/ui/2016257946

Clinicopathologic Analysis of 6 Lymphomatoid Gastropathy Cases

Katsuyoshi Takata, Mai Noujima-Harada, Tomoko Miyata-Takata, Koichi Ichimura, Yasuharu Sato, Takafumi Miyata, Keishi Naruse, Toshiyuki Iwamoto, Akira Tari, Taro Masunari, Hiroshi Sonobe, Hiroyuki Okada, Masaya Iwamuro, Kohichi Mizobuchi, Yuka Gion, Tadashi Yoshino

American Journal of Surgical Pathology 39 ( 9 ) 1259 - 1266 2015.9

サイトメガロウイルス感染による上部消化管病変の検討

岩室雅也, 近藤英生, 大塚文男, 岡田裕之, 山本和秀

Gastroenterological Endoscopy 57 ( Suppl.2 ) 2102 - 2102 2015.9

【消化管原発悪性リンパ腫】濾胞性リンパ腫の長期経過

岡田裕之, 岩室雅也, 高田尚良, 田中健大, 近藤英生, 河原祥朗, 川野誠司, 喜多雅英, 神崎洋光, 吉野正

消化器内視鏡 27 ( 5 ) 804 - 810 2015.5

Language：Japanese Publisher：(株)東京医学社

消化管濾胞性リンパ腫の治療への奏効率は高い。再燃も比較的高率に認められるが長期予後が得られている。watch and wait例も相当数認められ、一部は増悪しているが生存率への影響は少ない。本邦における多施設共同研究では、Lugano臨床病期stage I、II1 125例において、経過観察期間中央値40ヵ月(6〜148ヵ月)で原病死例はなく、6例(5%)が増悪した(初期治療:watch and wait 3例、rituximabを含んだ多剤併用化学療法2例、rituximab単独1例)。5年全生存率および無増悪生存率は100%および93%であった。生命予後を規定するのは、びまん性大細胞型リンパ腫への転化であり、転化率は10〜17%/5年、転化後の全生存率は中央値1.2〜4年と報告されている。限局期例が多い消化管濾胞性リンパ腫での検討は、いまだ不十分である。(著者抄録)

researchmap

【腸管悪性リンパ腫】臨床 Mantle cell lymphoma

岡田裕之, 岩室雅也, 田中健大, 近藤英生, 吉野正

Intestine 19 ( 3 ) 260 - 267 2015.5

Language：Japanese Publisher：(株)日本メディカルセンター

Mantle cell lymphoma(MCL)はリンパ濾胞のマントル層を構成するB細胞性リンパ腫である.遺伝子異常としてはt(11;14)(q13;q32)転座がある.約75%が診断時にすでにIII/IV期の進行期であると報告されており,消化管浸潤は高率に認められる.腸管病変としてはmultiple lymphomatous polyposisを呈する場合が多い.MCLの生存率の中央値は48〜68ヵ月と報告されている.通常のCHOP療法,あるいはリツキシマブ併用CHOP療法の治療強度を高めるためにhyper-CVAD/MA療法が考案され,長期生存がみられている.また,本治療後に自己末梢血幹細胞移植併用の大量化学療法を行うことにより,完全寛解率,無再発生存率が向上することが報告されている.(著者抄録)

researchmap

　 PREV - NEXT 　

< IWAMURO Masaya >

MISC - IWAMURO Masaya